Mr Oliver Keh, 23, was diagnosed with advanced inflammatory myofibroblastic tumours (IMT) as a teenager. Dr Anand Jeyasekharan, Consultant, Department of Haematology-Oncology, NCIS, said the typical survival prognosis for aggressive IMT ranges from one to two years after diagnosis. Mr Keh had been on different drug regimens since 2017, but a breakthrough finally came in June 2023 when Dr Jeyasekharan started him on Ceritinib, an oral medication usually used to treat patients with stage 4 lung cancer. After three months, Mr Keh's tumours vanished and could no longer be detected on scans. Dr Jeyasekharan said this could be the first report in the world of Ceritinib being used for this sub-type of IMT and his team plans to report on this in a medical journal. >>> Read the full article here
https://lnkd.in/gNUv3yby #NCISfightscancer